The abstract is read at the publisher; the summary is JClub's.
Multigene-engineered fibroblast-derived nanovesicles (X-Fb-MNVs) coexpressing CXCR4, iRGD, PD-1, and CD47 achieve robust, broad-spectrum tumor targeting across breast, liver, pancreatic, and colon cancer PDX models.
- Why it matters: Clinical translation of biomimetic vesicles is limited by biosafety, scalability, and insufficient therapeutic efficacy, motivating a platform that improves tumor homing while reducing off-target effects.
- What they did: Autologous fibroblasts were engineered to produce X-Fb-MNVs, and CD47 modification reduced hepatic accumulation and phagocytic clearance; diABZI STING agonist was loaded with PD-1 overexpression to activate T cell and innate immunity.
- The result: In PDX-bearing mice, the diABZI STING-loaded X-Fb-MNVs reversed ICB resistance and achieved 83.3% survival with no tumor recurrence and immune surveillance over 90 d, while no mice survived with free diABZI treatment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.